ArticleCancer2017

Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?

Maximilian Stahl et al.PubMed ↗Publisher ↗

No numbers read from the abstract.